Skip to main content
Erschienen in: Critical Care 2/2012

01.04.2012 | Review

Human albumin in the management of complications of liver cirrhosis

verfasst von: Mauro Bernardi, Caterina Maggioli, Giacomo Zaccherini

Erschienen in: Critical Care | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Excerpt

Human serum albumin is the most abundant plasma protein, representing about 50% of the total protein content (3.5-5 g/l). Albumin is a protein of 585 amino acids and molecular weight 66 kDa encoded by a gene on chromosome 4 and is exclusively synthesized by liver cells, which release it directly into the blood stream without storage. Under physiological conditions, only 20-30% of hepatocytes are committed to the production of 9-12 g of albumin per day; therefore, the liver has a large functional reserve, so that it can increase the synthesis of this protein by 3-4 times, if necessary. The production of albumin is mainly regulated by the osmolarity and oncotic pressure of interstitial fluid in the liver extravascular space, but it is also induced by hormonal factors (insulin, cortisol and growth hormone) and inhibited by acute phase cytokines, such as interleukin (IL)-6 and tumor necrosis factor (TNF)-α [1]. …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Quinlan GJ, Martin GS, Evans TW: Albumin: biochemical properties and therapeutic potential. Hepatology 2005, 41: 1211-1219. 10.1002/hep.20720CrossRefPubMed Quinlan GJ, Martin GS, Evans TW: Albumin: biochemical properties and therapeutic potential. Hepatology 2005, 41: 1211-1219. 10.1002/hep.20720CrossRefPubMed
2.
Zurück zum Zitat Mirici-Cappa F, Caraceni P, Domenicali M, et al.: How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. World J Gastroenterol 2011, 17: 3479-3486. 10.3748/wjg.v17.i30.3479PubMedCentralCrossRefPubMed Mirici-Cappa F, Caraceni P, Domenicali M, et al.: How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. World J Gastroenterol 2011, 17: 3479-3486. 10.3748/wjg.v17.i30.3479PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, SAFE Study Investigators: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004, 350: 2247-2256.CrossRefPubMed Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R, SAFE Study Investigators: A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004, 350: 2247-2256.CrossRefPubMed
4.
Zurück zum Zitat Delaney AP, Dan A, McCaffrey J, Finfer S: The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med 2011, 39: 386-391. 10.1097/CCM.0b013e3181ffe217CrossRefPubMed Delaney AP, Dan A, McCaffrey J, Finfer S: The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med 2011, 39: 386-391. 10.1097/CCM.0b013e3181ffe217CrossRefPubMed
5.
Zurück zum Zitat Vincent JL: Relevance of albumin in modern critical care medicine. Best Pract Res Clin Anaesthesiol 2009, 23: 183-191. 10.1016/j.bpa.2008.11.004CrossRefPubMed Vincent JL: Relevance of albumin in modern critical care medicine. Best Pract Res Clin Anaesthesiol 2009, 23: 183-191. 10.1016/j.bpa.2008.11.004CrossRefPubMed
6.
Zurück zum Zitat Evans TW: Review article: albumin as a drug. Biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002, 16: S6-S11. 10.1046/j.1365-2036.16.s5.2.xCrossRef Evans TW: Review article: albumin as a drug. Biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002, 16: S6-S11. 10.1046/j.1365-2036.16.s5.2.xCrossRef
7.
Zurück zum Zitat Oettl K, Stauber RE: Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 2007, 151: 580-590. 10.1038/sj.bjp.0707251PubMedCentralCrossRefPubMed Oettl K, Stauber RE: Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 2007, 151: 580-590. 10.1038/sj.bjp.0707251PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Sharma R, Gaze DC, Pellerin D, et al.: Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006, 47: 493-502. 10.1053/j.ajkd.2005.11.026CrossRefPubMed Sharma R, Gaze DC, Pellerin D, et al.: Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006, 47: 493-502. 10.1053/j.ajkd.2005.11.026CrossRefPubMed
9.
Zurück zum Zitat Van Belle E, Dallongeville J, Vicaut E, Degrandsart A, Baulac C, Montalescot G, OPERA Investigators: Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. Am Heart J 2010, 159: 570-576. 10.1016/j.ahj.2009.12.026CrossRefPubMed Van Belle E, Dallongeville J, Vicaut E, Degrandsart A, Baulac C, Montalescot G, OPERA Investigators: Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. Am Heart J 2010, 159: 570-576. 10.1016/j.ahj.2009.12.026CrossRefPubMed
10.
Zurück zum Zitat Henricksen JH, Siemssen O, Krintel JJ, Malchow-Møller A, Bendtsen F, Ring-Larsen H: Dynamics of albumin in plasma and acitic fluid in patients with cirrhosis. J Hepatol 2001, 34: 53-60.CrossRef Henricksen JH, Siemssen O, Krintel JJ, Malchow-Møller A, Bendtsen F, Ring-Larsen H: Dynamics of albumin in plasma and acitic fluid in patients with cirrhosis. J Hepatol 2001, 34: 53-60.CrossRef
11.
Zurück zum Zitat Wood LJ, Colman J, Dudley FJ: The relationship between portal pressure and plasma albumin in the development of cirrhotic ascites. J Gastroenterol Hepatol 1987, 2: 525-531. 10.1111/j.1440-1746.1987.tb00200.xCrossRef Wood LJ, Colman J, Dudley FJ: The relationship between portal pressure and plasma albumin in the development of cirrhotic ascites. J Gastroenterol Hepatol 1987, 2: 525-531. 10.1111/j.1440-1746.1987.tb00200.xCrossRef
12.
Zurück zum Zitat Rector WG Jr, Ibarra F, Openshaw K, Hoefs JC: Ascites kinetics in cirrhosis: relationship to plasma-ascites hydrostatic-oncotic balance and intensity of renal sodium retention. J Lab Clin Med 1986, 107: 412-419.PubMed Rector WG Jr, Ibarra F, Openshaw K, Hoefs JC: Ascites kinetics in cirrhosis: relationship to plasma-ascites hydrostatic-oncotic balance and intensity of renal sodium retention. J Lab Clin Med 1986, 107: 412-419.PubMed
13.
Zurück zum Zitat Møller S, Henriksen JH: Cardiovascular complications of cirrhosis. Gut 2008, 57: 268-278. 10.1136/gut.2006.112177CrossRefPubMed Møller S, Henriksen JH: Cardiovascular complications of cirrhosis. Gut 2008, 57: 268-278. 10.1136/gut.2006.112177CrossRefPubMed
14.
Zurück zum Zitat Ginés P, Titó L, Arroyo V, et al.: Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1998, 94: 1493-1502. Ginés P, Titó L, Arroyo V, et al.: Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1998, 94: 1493-1502.
15.
Zurück zum Zitat Sort P, Navasa M, Arroyo V, et al.: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341: 403-409. 10.1056/NEJM199908053410603CrossRefPubMed Sort P, Navasa M, Arroyo V, et al.: Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341: 403-409. 10.1056/NEJM199908053410603CrossRefPubMed
16.
Zurück zum Zitat Martín-Llahí M, Pépin MN, Guevara M, et al.: Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008, 134: 1352-1359. 10.1053/j.gastro.2008.02.024CrossRefPubMed Martín-Llahí M, Pépin MN, Guevara M, et al.: Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008, 134: 1352-1359. 10.1053/j.gastro.2008.02.024CrossRefPubMed
17.
Zurück zum Zitat Sanyal AJ, Boyer T, Garcia-Tsao G, et al.: A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134: 1360-1368. Sanyal AJ, Boyer T, Garcia-Tsao G, et al.: A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134: 1360-1368.
18.
Zurück zum Zitat Ginès A, Fernandez-Esparrach G, Monescillo A, et al.: Randomized controlled trial comparing albumin, dextran-70 and polygelin in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111: 1002-1010. Ginès A, Fernandez-Esparrach G, Monescillo A, et al.: Randomized controlled trial comparing albumin, dextran-70 and polygelin in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 111: 1002-1010.
19.
Zurück zum Zitat European Association for the Study of the Liver: EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010, 53: 397-417.CrossRef European Association for the Study of the Liver: EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010, 53: 397-417.CrossRef
20.
Zurück zum Zitat Moreau R, Valla DC, Durand-Zaleski I, et al.: Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int 2006, 26: 46-54. 10.1111/j.1478-3231.2005.01188.xCrossRefPubMed Moreau R, Valla DC, Durand-Zaleski I, et al.: Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail. Liver Int 2006, 26: 46-54. 10.1111/j.1478-3231.2005.01188.xCrossRefPubMed
21.
Zurück zum Zitat Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007, 56: 1310-1318.PubMedCentralPubMed Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V: Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007, 56: 1310-1318.PubMedCentralPubMed
22.
Zurück zum Zitat Ginès P, Schrier RW: Renal failure in cirrhosis. N Engl J Med 2009, 361: 1279-1290. 10.1056/NEJMra0809139CrossRefPubMed Ginès P, Schrier RW: Renal failure in cirrhosis. N Engl J Med 2009, 361: 1279-1290. 10.1056/NEJMra0809139CrossRefPubMed
23.
Zurück zum Zitat Ortega R, Gines P, Uriz J, et al.: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of prospective, non-randomized study. Hepatology 2002, 36: 941-948.CrossRefPubMed Ortega R, Gines P, Uriz J, et al.: Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of prospective, non-randomized study. Hepatology 2002, 36: 941-948.CrossRefPubMed
24.
Zurück zum Zitat Gluud LL, Christensen K, Christensen E, Krag A: Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010, 51: 576-584. 10.1002/hep.23286CrossRefPubMed Gluud LL, Christensen K, Christensen E, Krag A: Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome. Hepatology 2010, 51: 576-584. 10.1002/hep.23286CrossRefPubMed
25.
Zurück zum Zitat Angeli P, Volpin R, Gerunda G, et al.: Reversal of type 1 hepatorenal syndrome (HRS) with the combined administration of midodrine and octreotide. Hepatology 1999, 29: 1690-1697. 10.1002/hep.510290629CrossRefPubMed Angeli P, Volpin R, Gerunda G, et al.: Reversal of type 1 hepatorenal syndrome (HRS) with the combined administration of midodrine and octreotide. Hepatology 1999, 29: 1690-1697. 10.1002/hep.510290629CrossRefPubMed
26.
Zurück zum Zitat Alessandria C, Ottobrelli A, Debernardi-Venon W, et al.: Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007, 47: 499-505. 10.1016/j.jhep.2007.04.010CrossRefPubMed Alessandria C, Ottobrelli A, Debernardi-Venon W, et al.: Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol 2007, 47: 499-505. 10.1016/j.jhep.2007.04.010CrossRefPubMed
27.
Zurück zum Zitat Caraceni P, Santi L, Mirici F, et al.: Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. Dig Liver Dis 2011, 43: 242-245. 10.1016/j.dld.2010.08.001CrossRefPubMed Caraceni P, Santi L, Mirici F, et al.: Long-term treatment of hepatorenal syndrome as a bridge to liver transplantation. Dig Liver Dis 2011, 43: 242-245. 10.1016/j.dld.2010.08.001CrossRefPubMed
28.
Zurück zum Zitat Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M: Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007, 56: 597-599. 10.1136/gut.2006.113050PubMedCentralCrossRefPubMed Sigal SH, Stanca CM, Fernandez J, Arroyo V, Navasa M: Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007, 56: 597-599. 10.1136/gut.2006.113050PubMedCentralCrossRefPubMed
29.
Zurück zum Zitat Fernández J, Monteagudo J, Bargallo X, et al.: A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005, 42: 627-634. 10.1002/hep.20829CrossRefPubMed Fernández J, Monteagudo J, Bargallo X, et al.: A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005, 42: 627-634. 10.1002/hep.20829CrossRefPubMed
30.
Zurück zum Zitat Clermont RJ, Vlahevic ZR, Chalmers TC, Adham NF, Curtis GW, Morrosin RS: Intravenous therapy of massive ascites in patients with cirrhosis. Long-term effects on survival and frequency of renal failure. Gastroenterology 1967, 53: 220-228. Clermont RJ, Vlahevic ZR, Chalmers TC, Adham NF, Curtis GW, Morrosin RS: Intravenous therapy of massive ascites in patients with cirrhosis. Long-term effects on survival and frequency of renal failure. Gastroenterology 1967, 53: 220-228.
31.
Zurück zum Zitat Gentilini P, Casini-Raggi V, Di Fiore G, et al.: Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999, 30: 639-645. 10.1016/S0168-8278(99)80194-9CrossRefPubMed Gentilini P, Casini-Raggi V, Di Fiore G, et al.: Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999, 30: 639-645. 10.1016/S0168-8278(99)80194-9CrossRefPubMed
32.
Zurück zum Zitat Romanelli RG, La Villa G, Barletta G, et al.: Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006, 12: 1403-1407.PubMedCentralPubMed Romanelli RG, La Villa G, Barletta G, et al.: Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006, 12: 1403-1407.PubMedCentralPubMed
33.
Zurück zum Zitat Watanabe A, Matsuzaki S, Moriwaki H, Suzuki K, Nishiguchi S: Problems in serum albumin measurement and clinical significance of albumin microheterogeneity in cirrhotics. Nutrition 2004, 20: 351-357. 10.1016/j.nut.2003.12.006CrossRefPubMed Watanabe A, Matsuzaki S, Moriwaki H, Suzuki K, Nishiguchi S: Problems in serum albumin measurement and clinical significance of albumin microheterogeneity in cirrhotics. Nutrition 2004, 20: 351-357. 10.1016/j.nut.2003.12.006CrossRefPubMed
34.
Zurück zum Zitat Oettl K, Stadlbauer V, Petter F, et al.: Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 2008, 1782: 469-473.CrossRefPubMed Oettl K, Stadlbauer V, Petter F, et al.: Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta 2008, 1782: 469-473.CrossRefPubMed
35.
Zurück zum Zitat Jalan R, Schnurr K, Mookerjee RP, et al.: Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009, 50: 555-564.CrossRefPubMed Jalan R, Schnurr K, Mookerjee RP, et al.: Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009, 50: 555-564.CrossRefPubMed
36.
Zurück zum Zitat Oettl K, Stadlbauer V, Krisper P, Stauber RE: Effect of extracorporeal liver support by molecular adsorbents recirculating system and Prometheus on redox state of albumin in acute-on-chronic liver failure. Ther Apher Dial 2009, 13: 431-436. 10.1111/j.1744-9987.2009.00762.xCrossRefPubMed Oettl K, Stadlbauer V, Krisper P, Stauber RE: Effect of extracorporeal liver support by molecular adsorbents recirculating system and Prometheus on redox state of albumin in acute-on-chronic liver failure. Ther Apher Dial 2009, 13: 431-436. 10.1111/j.1744-9987.2009.00762.xCrossRefPubMed
37.
Zurück zum Zitat Karvellas CJ, Gibney N, Kutsogiannis D, Wendon J, Bain VG: Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure. Crit Care 2007, 11: 215. 10.1186/cc5922PubMedCentralCrossRefPubMed Karvellas CJ, Gibney N, Kutsogiannis D, Wendon J, Bain VG: Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure. Crit Care 2007, 11: 215. 10.1186/cc5922PubMedCentralCrossRefPubMed
38.
Zurück zum Zitat Bañares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, Relief Study Group: Extracorporeal liver support with the molecular adsorbent recirculating system (MARS) in patients with acute-on-chronic liver failure (AOCLF). The RELIEF Trial. J Hepatol 2010, 52: S459-S460.CrossRef Bañares R, Nevens F, Larsen FS, Jalan R, Albillos A, Dollinger M, Relief Study Group: Extracorporeal liver support with the molecular adsorbent recirculating system (MARS) in patients with acute-on-chronic liver failure (AOCLF). The RELIEF Trial. J Hepatol 2010, 52: S459-S460.CrossRef
39.
Zurück zum Zitat Rifai K, Kribben A, Gerken G, et al.: Extracorporeal liver support by fractionated plasma separation and adsorption (PROMETHEUS) in patients with acute-on-chronic liver failure (HELIOS Study): a prospective randomized controlled multicenter study. J Hepatol 2010, 52: S3.CrossRef Rifai K, Kribben A, Gerken G, et al.: Extracorporeal liver support by fractionated plasma separation and adsorption (PROMETHEUS) in patients with acute-on-chronic liver failure (HELIOS Study): a prospective randomized controlled multicenter study. J Hepatol 2010, 52: S3.CrossRef
Metadaten
Titel
Human albumin in the management of complications of liver cirrhosis
verfasst von
Mauro Bernardi
Caterina Maggioli
Giacomo Zaccherini
Publikationsdatum
01.04.2012
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 2/2012
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc11218

Weitere Artikel der Ausgabe 2/2012

Critical Care 2/2012 Zur Ausgabe

Tipps für den Umgang mit Behandlungsfehlern

01.05.2024 DGIM 2024 Kongressbericht

Es ist nur eine Frage der Zeit, bis es zu einem Zwischenfall kommt und ein Behandlungsfehler passiert. Doch wenn Ärztinnen und Ärzte gut vorbereitet sind, schaffen es alle Beteiligten den Umständen entsprechend gut durch diese Krise. 

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.